NeuroSigma
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10960 Wilshire Blvd Ste 1910, Los Angele...Phone Number
(310) 479-3100Website
www.neurosigma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About NeuroSigma
NeuroSigma is a California-based life sciences company established to develop bioelectronic technologies with the potential to transform medical practice and patients' lives. NeuroSigma is focused on TNS bioelectronics therapies based on intellectual property, licensed on an exclusive basis from the University of California, Los Angeles (UCLA), covering a wide-spectrum of disorders, including ADHD.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NeuroSigma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if NeuroSigma had a recent Job posting/layoffs
Check if NeuroSigma has recently received funding, and reach out quickly before it becomes old news!
NeuroSigma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once NeuroSigma has new funding data
Congratulate Masked Content for being promoted to Masked Content at NeuroSigma
Product Launch: Get notified when NeuroSigma launches new products
Website visits: Recent activity has been detected on your website
Check out if NeuroSigma is spiking on competitors!
Earning: See what the market has to say on NeuroSigma recently announced quarterly report
Recommended Actions
Find VP level buyers at NeuroSigma
Find 2 more new buyers
Compare Similar Companies to NeuroSigma
Compare insights from companies similar to NeuroSigma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NeuroSigma
<$5M
11-50
Private
$16.8M
2008
N/A
$28.3M
51-200
Private
$130.7M
2010
Eric TimmPresident & Global CEO, Commercial Operations & Neuromod (USA)
Company Profile Activity
Activity Insights
NeuroSigma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NeuroSigma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NeuroSigma.
NeuroSigma financials insights
Gather financial insights about NeuroSigma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$11.7M
2021
Debt
$132K
Corporate Investment
$5M
NeuroSigma Tech Stack
A closer look at the technologies used by NeuroSigma
Most Recent Scoops
Project
Intellectual Property, Legal Affairs, Healthcare Technology
Funding
Funding
NeuroSigma has received an SBA PPP loan in the amount of $132,580 from Bank of America resulting in the retention of 7 jobs.
Funding
NeuroSigma News & Media
NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device
LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced completion of an approximately $1 million investment into a high-volume manufacturing line for the second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating pediatric attention-deficit/hyperactivity disorder (ADHD). NeuroSigma’s manufacturing partner for the project is Singapore-based Armstrong Asia, a leading manufacturer for the medical,NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program
Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launch Company dispensed over 1,000 FDA-cleared systems in pilot phase; unveils new website and second-generation device for early 2026 launchNeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNS Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNSNeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma’s core eTNS technology, including its seco
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NeuroSigma
Sign Up For FreeTo access detailed company insights
NeuroSigma is a California-based life sciences company established to develop bioelectronic technologies with the potential to transform medical practice and patients' lives. NeuroSigma is focused on TNS bioelectronics therapies based on intellectual property, licensed on an exclusive basis from the University of California, Los Angeles (UCLA), cov... Read More
